KRAS and cancer: Encouraged by the observation that the combination treatment potentiates the RIG-I activation in KRAS mutant-driven cancer cells, we investigated the infiltration of human peripheral blood mononuclear cells (PBMCs) into the cancer spheroids after the treatment (Figure 3A).